<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750980</url>
  </required_header>
  <id_info>
    <org_study_id>02e14</org_study_id>
    <nct_id>NCT04750980</nct_id>
  </id_info>
  <brief_title>Microbiota and Allergy</brief_title>
  <acronym>MATFA I</acronym>
  <official_title>Microbiota as Potential Target for Innovative Preventive and Therapeutic Strategies for Food Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Food allergy derives from a dysregulation of oral tolerance mechanisms. Studies suggest a&#xD;
      crucial role for gut microbiota in oral tolerance development. An altered composition of gut&#xD;
      microbiota results in an unbalanced local and systemic immune response to food allergens.&#xD;
      There are qualitative and quantitative differences in gut microbiota composition in children&#xD;
      with food allergy. Preliminary results of MATFA study demonstrated gut microbiota in allergic&#xD;
      children.These findings support the pivotal role of the gut microbiota in the pathogenesis of&#xD;
      allergic diseases and may open new strategies in the development of innovative preventive and&#xD;
      therapeutic approaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">January 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of gut microbiome features in allergic children and in healthy controls.</measure>
    <time_frame>at enrollment</time_frame>
    <description>Comparatively evaluation of gut microbiome features in allegic children and in healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome and allergy disease course</measure>
    <time_frame>at enrollment</time_frame>
    <description>Evaluation of gut microbiome influence on allergy disease course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of gut microbiome features in children affected by different allergies (food and respiratory)</measure>
    <time_frame>at enrollment</time_frame>
    <description>Comparatively evaluation of gut microbiome features in children with different allergies (food and respiratory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of gut microbiome features in children affected by different type of food allergy</measure>
    <time_frame>at enrollment</time_frame>
    <description>Evaluation of gut microbiome features in children affected by different type of food allergy</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Food allergy</arm_group_label>
    <description>Childen with food allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respiratory allergy</arm_group_label>
    <description>Children with respiratory allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>food allergy</intervention_name>
    <description>food allergy</description>
    <arm_group_label>Food allergy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>respiratory allergy</intervention_name>
    <description>respiratory allergy</description>
    <arm_group_label>Respiratory allergy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>healthy controls</intervention_name>
    <description>healthy controls</description>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with food allergy, children with respiratory allergy and health controls aged&#xD;
        48-84 months&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children with sure diagnosis of food allergy,&#xD;
&#xD;
          -  children with sure diagnosis of respiratory allergy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age at enrollment &lt;48 months or &gt;84 months;&#xD;
&#xD;
          -  eosinophilic disorders of the gastrointestinal tract;&#xD;
&#xD;
          -  chronic systemic diseases;&#xD;
&#xD;
          -  congenital cardiac defects;&#xD;
&#xD;
          -  acute or chronic infections;&#xD;
&#xD;
          -  autoimmune diseases;&#xD;
&#xD;
          -  immunodeficiencies;&#xD;
&#xD;
          -  chronic inflammatory bowel diseases;&#xD;
&#xD;
          -  celiac disease;&#xD;
&#xD;
          -  cystic fibrosis or other forms of primary pancreatic insufficiency;&#xD;
&#xD;
          -  genetic and metabolic diseases;&#xD;
&#xD;
          -  food intolerances;&#xD;
&#xD;
          -  malignancy;&#xD;
&#xD;
          -  chronic pulmonary diseases;&#xD;
&#xD;
          -  malformations of the respiratory tract or of the gastrointestinal tract;&#xD;
&#xD;
          -  pre-, pro- or sinbiotic use in the previous 3 months;&#xD;
&#xD;
          -  antibiotics or gastric acidity inhibitors use in the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>48 Months</minimum_age>
    <maximum_age>84 Months</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Department of Traslational Medical Science - University of Naples Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Roberto Berni Canani</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

